Independent review of EO Care’s model for quantifying theoretical healthcare cost impacts in the United States
EO Care is a digital health platform that provides guidance for cannabinoid-based treatments. The company has developed a model for group plan sponsors to estimate the theoretical healthcare cost impacts of using evidence-based, clinically guided cannabinoids to mitigate symptoms of cancer, chronic pain, sleep disorders and insomnia, and anxiety. EO Care recently commissioned Milliman to review its model methodology to determine its appropriateness. This report:
- Describes EO Care’s approach to determining the model’s input values
- Outlines EO Care’s approach for estimating theoretical healthcare cost impacts for group plan sponsors
- Discusses potential limitations of the methodology
- Outlines important caveats and limitations
This report was commissioned by EO Care.
About the Author(s)
Independent review of EO Care’s model for quantifying theoretical healthcare cost impacts in the United States
We take a close look at a digital health platform’s methodology to help plan sponsors estimate theoretical healthcare cost impacts of using cannabinoids.